Chagas Disease Treatment Market - Industry Insights, Trends, Opportunity And AnaPosted by Rajkumar on July 18th, 2019 Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America, due to migration of people from Latin America to others countries. For instance, according a study published in National Center for Biotechnology Information (NCBI), in 2015, 4.2% of Latin American living in European countries were chronically affected with Chagas disease. Benznidazole is the only FDA approved treatment indicated for the treatment of Chagas disease. However, the drug, Nifurtimox manufactured by Bayer AG, is in the World Health Organization's (WHO) list of 'Essential Medicines' and used in the treatment of Chagas disease. Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/934 Increasing approval to Chagas disease treatment drugs is expected to drive growth of the global Chagas disease treatment market Benznidazole is an essential antiparasitic drug used for the treatment of Chagas disease. In April 2018, Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT) approved Laboratorio Elea Phoenix SA’s drug benznidazole for pediatric indication used for the treatment of Chagas disease. Currently, Argentina has the highest number of people suffering from Chagas disease. For instance, according to data published by Mundo Sano (Nongovernmental foundation in Argentina), in 2017, around 7,300,000 people were exposed to Chagas disease and about 1,600,000 were infected, in Argentina. Hence, approval of novel drugs is expected to fuel the market growth in the near future. Such approval of Chagas disease treatment drugs is expected to boost growth of Chagas disease treatment market in the near future. The global Chagas treatment disease market was valued at US$ 5.67 Mn in 2016 and is expected to witness a CAGR of 7.3% over the forecast period (2017–2025). Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/market-insight/chagas-disease-treatment-market-934 Market Dynamics Rising migration of people from endemic countries to developed economies such as the U.S. and in countries in Europe is expected to drive growth of Chagas disease treatment market. For instance, according to the data published by Public Library of Science (PLOS), in 2012, there are around 1,62,095 Bolivian adults living in Spain, in which about 97,215 are women (60%) and 64,880 are men. It was estimated that out of total immigrants from Bolivia to Spain 34,202 were found to be potentially infected with Chagas disease. Furthermore, increasing R&D activities for the development of novel treatment methods for Chagas disease is also expected to create a lucrative environment for the market growth. For instance, in 2016, researchers from Saint Louis University Center for Vaccine Development were working on developing a vaccine for Chagas disease. Scientists found Th17 cells, a special type of white blood cell that recognizes the presence of a foreign invader and helps other cells in the immune system to attack and protects the body against Trypanosoma cruzi parasite. Key players operating in the Chagas disease treatment market include Nortec Quimica SA, Bayer AG, Laboratorio Elea Phoenix SA, Maprimed S.A., and Laboratório Farmacêutico de Pernambuco S/A. About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Like it? Share it! More by this author |